Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05514535 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 573
- Enrollment target
NCT05514535 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 573 participants.
The verdict
NCT05514535, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 573 participants
- Enrollment target
Study Summary
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.
Interventions
- DRUG Semaglutide
- DRUG Insuline glargine U100 (reduced)
- DRUG Insuline glargine U100 (titrated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 573 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2025-04-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05514535
The ClinicalTrials.gov registry entry for NCT05514535 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 573 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Semaglutide is the first listed.
NCT05514535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05514535 about?
NCT05514535 is a clinical study titled "A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)". This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dos...
What is the current status of trial NCT05514535?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 573 participants. The study started on 2022-08-29. Estimated completion is 2025-04-09.
What interventions are being tested in trial NCT05514535?
The interventions under investigation include: Semaglutide (DRUG), Insuline glargine U100 (reduced) (DRUG), Insuline glargine U100 (titrated) (DRUG).
Who is sponsoring clinical trial NCT05514535?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.